Cited by 288Monoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical MethodsPharmaceutical studies and practices

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?

Open access

Deng, Rong, Iyer, Suhasini, Theil, Frank-Peter, Mortensen, Deborah L., Fielder, Paul J., Prabhu, Saileta·2011·mAbs

DOI 10.4161/mabs.3.1.13799PMC PMC3038012

Open this paper in CoChat — free account Open PDF

Abstract

The pharmacokinetics (PK) of therapeutic antibodies is determined by target and non-target mediated mechanisms. These antibody-specific factors need to be considered during prediction of human PK based upon preclinical information. Principles of allometric scaling established for small molecules using data from multiple animal species cannot be directly applied to antibodies. Here, different methods for projecting human clearance (CL) from animal PK data for 13 therapeutic monoclonal antibodies (mAbs) exhibiting linear PK over the tested dose ranges were examined: simple allometric scaling (CL versus body weight), allometric scaling with correction factors, allometric scaling based on rule of exponent and scaling from only cynomolgus monkey PK data. A better correlation was obtained between the observed human CL and the estimated human CL based on cynomolgus monkey PK data and an allometric scaling exponent of 0.85 for CL than other scaling approaches. Human concentration-time profiles were also reasonably predicted from the cynomolgus monkey data using species-invariant time method with a fixed exponent of 0.85 for CL and 1.0 for volume of distribution. In conclusion, we expanded our previous work and others and further confirmed that PK from cynomolgus monkey alone can be successfully scaled to project human PK profiles within linear range using simplify allometry and Dedrick plots with fixed exponent.

Integrity signals

Registry

Crossref · 10.4161/mabs.3.1.13799

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,930
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization
West, G. B., & Brown, J. H. (2005) · Journal of Experimental Biology · doi:10.1242/jeb.01589 · Cited by 806
To Scale or Not to Scale: The Principles of Dose Extrapolation
Sharma, V., & McNeill, J. H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00267.x · Cited by 544
Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies
Ober, R. J., Radu, C. G., Ghetie, V. F., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 502
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Animal Scale-Up
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397
Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B. Y., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm
Boxenbaum, H. G. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033558 · Cited by 270
Interspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 1

Deng R, 2007, Prediction of human pharmacokinetics for monoclonal antibody

Sorted by citations

Items 101–200 of 288

Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys
Glassman, P. M., Chen, Y., & Balthasar, J. P. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9444-y · Cited by 28
Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics
Sukumaran, S., Zhang, C., Leipold, D. D., Saad, O. M., Xu, K., Gadkar, K. G., Samineni, D., Wang, B., Milojic-Blair, M., Carrasco‐Triguero, M., et al. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9993-z · Cited by 27
Self-citation
Use of Generic LC–MS/MS Assays to Characterize Atypical PK Profile of A Biotherapeutic Monoclonal Antibody
Law, W. S., Genin, J., Miess, C., Tréton, G., Warren, A. P., Lloyd, P. M., Dudal, S., & Krantz, C. (2014) · Bioanalysis · doi:10.4155/bio.14.167 · Cited by 26
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28
A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide
Offman, E. M., & Edginton, A. N. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9406-4 · Cited by 26
Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies
Luu, K. T., Kraynov, E. A., Kuang, B., Vicini, P., & Zhong, W.-Z. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9464-8 · Cited by 26
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
Xue, J., Kong, D., Yao, Y., Yang, L., Yao, Q., Zhu, Y., Ding, Y., Yang, F., Gong, J., Shen, L., et al. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.06.015 · Cited by 25
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper
Ménochet, K., Yu, H., Wang, B., Tibbitts, J., Hsu, C., Kamath, A. V., Richter, W. F., & Baumann, A. (2022) · mAbs · doi:10.1080/19420862.2022.2145997 · Cited by 25
Tools for predicting the PK/PD of therapeutic proteins
Diao, L., & Meibohm, B. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1041917 · Cited by 25
Bioanalysis of Target Biomarker And Pk/Pd Relevancy During The Development of Biotherapeutics
Lee, J. W., & Salimi-Moosavi, H. (2012) · Bioanalysis · doi:10.4155/bio.12.220 · Cited by 24
Towardin vitro-to-in vivotranslation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms
Jaramillo, C. A. C., Belli, S., Cascais, A., Dudal, S., Edelmann, M. R., Haak, M., Brun, M.-E., Otteneder, M. B., Ullah, M., Funk, C., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1320008 · Cited by 25
Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study
Tabuchi, H., Katsurabara, T., Mori, M., Aoyama, M., Obara, T., Yasuda, N., Kawano, T., Imai, T., Ieiri, I., & Kumagai, Y. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1361 · Cited by 24
Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
Mo, G., Baldwin, J. R., Luffer, D. R., Ilaria, R. L., Conti, I., Heathman, M. A., & Cronier, D. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0562-0 · Cited by 23
Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys
Li, T. R., & Balthasar, J. P. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.065 · Cited by 23
Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500
Bonifacio, L., Dodds, M., Prohaska, D., Moss, A. M., Giaccia, A. J., Tabibiazar, R., & McIntyre, G. (2019) · Clinical and Translational Science · doi:10.1111/cts.12706 · Cited by 23
A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders
Gandhi, P. S., Živkovic, M., Østergaard, H., Bonde, A. C., Elm, T., Løvgreen, M. N., Schluckebier, G., Johansson, E., Olsen, O. H., Olsen, E. H. N., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00418-4 · Cited by 22
Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
Kamath, A. V., Lu, D., Gupta, P., Jin, D., Xin, Y., Brady, A., Stéphan, J.-P., Li, H., Tien, J., Qing, J., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1807-5 · Cited by 22
Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development
Ollier, R., Wassmann, P., Monney, T., Fecourt, C. R., Gn, S., Vinu, C., Ayoub, D., Stutz, C., Gudi, G. S., & Blein, S. (2019) · mAbs · doi:10.1080/19420862.2019.1660564 · Cited by 22
Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B
Vugmeyster, Y., Rohde, C. M., Perreault, M., Gimeno, R. E., & Singh, P. (2013) · mAbs · doi:10.4161/mabs.23826 · Cited by 22
Model‐Based Assessment of Dosing Strategies in Children for Monoclonal Antibodies Exhibiting Target‐Mediated Drug Disposition
Zheng, S., Gaitonde, P., Andrew, M., Gibbs, M. A., Lesko, L. J., & Schmidt, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.38 · Cited by 21
Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection
Pasquiers, B., Benamara, S., Felices, M., Nguyen, L., & Declèves, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112754 · Cited by 20
Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21–Antibody Protein Conjugate
Giragossian, C., Vage, C., Li, J., Pelletier, K. B., Piche‐Nicholas, N., Rajadhyaksha, M., Liras, J. L., Logan, A., Calle, R. A., & Weng, Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061713 · Cited by 20
Target‐mediated drug disposition modeling of an anti‐TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics
Kwak, E., Kim, M. J., Park, J. H., Jung, H. W., & Jung, M. E. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15244 · Cited by 19
Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide
Offman, E. M., Phipps, C. J., & Edginton, A. N. (2016) · In Silico Pharmacology · doi:10.1186/s40203-016-0018-5 · Cited by 19
Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations
Haraya, K., & Tachibana, T. (2022) · BioDrugs · doi:10.1007/s40259-022-00566-2 · Cited by 18
Anti‐infective immunoadhesins from plants
Wycoff, K. L., Maclean, J. M., Belle, A., Yu, L., Tran, T. H. Y., Roy, C. J., & Hayden, F. G. (2015) · Plant Biotechnology Journal · doi:10.1111/pbi.12441 · Cited by 18
Population Pharmacokinetics of Necitumumab in Cancer Patients
Long, A. J., Chigutsa, E., & Wallin, J. E. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0452-x · Cited by 18
Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A
Zheng, S., Shen, F., Jones, B. H., Fink, D., Geist, B. J., Nnane, I. P., Zhou, Z., Hall, J., Malaviya, R., Ort, T., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1770018 · Cited by 18
Quantitative Systems Pharmacology Model of a Masked, Tumor‐Activated Antibody
Stroh, M., Sagert, J. G., Burke, J. M., Apgar, J. F., Lin, L., Millard, B. L., & Kavanaugh, W. M. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12448 · Cited by 17
Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice
Kamath, A. V., Yip, V., Gupta, P., Boswell, C. A., Bumbaca, D., Haughney, P. C., Castro, J., Tsai, S. P., Pacheco, G., Ross, S., et al. (2014) · mAbs · doi:10.4161/mabs.36107 · Cited by 18
Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer
Li, C., Wang, J., Hu, J., Feng, Y., Hasegawa, K., Peng, X., Duan, X., Zhao, A., Mikitsh, J. L., Muzykantov, V. R., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2188 · Cited by 18
Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
Leipold, D. D., Figueroa, I., Masih, S., Latifi, B., Yip, V., Shen, B., Dere, R. C., Carrasco‐Triguero, M., Lee, M. V., Saad, O. M., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1517565 · Cited by 17
Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys
Dudal, S., Subramanian, K., Flandre, T., Law, W. S., Lowe, P. J., Skerjanec, A., Genin, J.-C., Duval, M., Piequet, A., Cordier, A., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1060384 · Cited by 16
American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates
Thudium, K. E., Bilic, S., Leipold, D. D., Mallet, W. G., Kaur, S., Meibohm, B., Erickson, H. K., Tibbitts, J., Zhao, H., & Gupta, M. (2013) · mAbs · doi:10.4161/mabs.22909 · Cited by 16
Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children
Capparelli, E. V., Ajibola, G., Maswabi, K., Holme, M. P., Bennett, K. K., Powis, K. M., Moyo, S. M., Mohammed, T., Maphorisa, C. N., Hughes, M. D., et al. (2022) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003033 · Cited by 16
Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics
Meibohm, B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_5 · Cited by 16
Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies
Hu, L., & Hansen, R. J. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23504 · Cited by 16
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development
Liao, M. Z., Leipold, D. D., Chen, S., Li, Z., Kamath, A. V., & Li, C. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2351044 · Cited by 15
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
Shastri, P. N., Shah, N., Lechmann, M., Mody, H. R., Retter, M. W., Zhu, M., Li, T. R., Wang, J., Shaik, M. N., Zheng, X., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3439 · Cited by 15
Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates
Bouillon‐Pichault, M., Brillac, C., Amara, C., Nicolazzi, C., Fagniez, N., Fau, J., Koiwai, K., Ziti‐Ljajic, S., & Veyrat‐Follet, C. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.869 · Cited by 15
Translational pharmacokinetic/pharmacodynamic model for mRNA‐0184, an investigational therapeutic for the treatment of heart failure
Kaushal, N., Attarwala, H. Z., Iqbal, M. J., Saini, R., Van, L. M., & Liang, M. (2024) · Clinical and Translational Science · doi:10.1111/cts.13894 · Cited by 14
Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics
Myzithras, M., Bigwarfe, T., Li, H., Waltz, E., Ahlberg, J., Giragossian, C., & Roberts, S. (2016) · mAbs · doi:10.1080/19420862.2016.1229721 · Cited by 14
Non‐Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First‐in‐Human Dose Selection for CNTO 5825, an Anti‐Interleukin‐13 Monoclonal Antibody
Nnane, I. P., Xu, Z., Zhou, H., & Davis, H. M. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12391 · Cited by 14
Monoclonal Antibodies: From Structure to Therapeutic Application
Davis, J. D., Deng, R., Boswell, C. A., Zhang, Y., Li, J., Fielder, P. J., Joshi, A., & Kenkare-Mitra, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_7 · Cited by 14
Self-citation
Nonclinical safety assessment of a human interleukin‐22 FC IG fusion protein demonstrates in vitro to in vivo and cross‐species translatability
Lee, D. W., Zhong, S., Pai, R., Rae, J., Sukumaran, S., Stefanich, E. G., Lutman, J., Doudement, E., Wang, X., Harder, B., et al. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.434 · Cited by 14
Pharmacokinetics and Toxicokinetics
Schrag, M. L., & Regal, K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00004-9 · Cited by 14
Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells
Gampa, G., Spinosa, P. C., Getz, J. A., Zhong, Y. M., Halpern, W., Esen, E., Davies, J., Chou, C. K., Kwong, M., Wang, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16326 · Cited by 13
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research
Zhang, Y., Doshi, S., & Zhu, M. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12663 · Cited by 13
Use of a Target‐Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC 1118, an Anti‐epidermal Growth Factor Receptor Antibody
Park, W., Han, S., Lee, J.-T., Hong, T., Won, J., Lim, Y., Lee, K., Byun, H. Y., & Yim, D. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12675 · Cited by 13
Modification of the Fc Region of a Human Anti‐oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half‐life in Cynomolgus Monkeys
Nnane, I. P., Han, C., Jiao, Q., Tam, S. H., Davis, H. M., & Xu, Z. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12761 · Cited by 13
A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans
Biliouris, K., Nestorov, I. A., Naik, H., Dai, D., Xiao, G., Wang, Q. L., Pellerin, A., Rabah, D., Lesko, L. J., & Trame, M. N. (2018) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-018-9609-6 · Cited by 13
A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults
Wang, J., Niu, S., Dong, W., Wei, L., Ou, L., Zhang, T., Zhang, L., Nie, X., Wang, Q., Shen, T., et al. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1770226 · Cited by 13
Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins
Meibohm, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-00710-2_6 · Cited by 13
Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems
Ahmed, S., Ellis, M., Li, H., Pallucchini, L., & Stein, A. M. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09638-3 · Cited by 13
Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development
Poloyac, S. M., Bertz, R., McDermott, L. A., & Marathe, P. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2018.6295 · Cited by 13
Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection
Xiang, H., Reyes, A. E., Eppler, S., Kelley, S. K., & Damico‐Beyer, L. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2200-3 · Cited by 12
Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies
Zhu, M., Olson, K., Kirshner, J. R., Toroghi, M. K., YAN, H. H., Haber, L., Meagher, C. T., Flink, D. M., Ambati, S. R., Davis, J. D., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13212 · Cited by 12
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
Groothuis, P. G., Jacobs, D. C. H., Hermens, I. A. T., Damming, D., Berentsen, K., Mattaar-Hepp, E., Stokman, M. E. M., van Boekel, T., Rouwette, M., van der Vleuten, M. A. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0596 · Cited by 12
Monoclonal Antibodies: Interspecies Scaling With Minimal Preclinical Information
Han, C., & Zhou, H. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.1 · Cited by 12
Integrated Two‐Analyte Population Pharmacokinetic Model for Antibody–Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling
Lu, D., Gibiansky, L. V., Agarwal, P., Dere, R., Li, C., Chu, Y., Hirata, J. H., Joshi, A., Jin, J., & Girish, S. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12137 · Cited by 12
Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies
Zhang, T., Ma, J., Durbin, K. R., Montavon, T. J., Lacy, S. E., Jenkins, G. J., Doktor, S. Z., & Kalvass, J. C. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0352-8 · Cited by 12
Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple Myeloma
Cai, H., Kakiuchi-Kiyota, S., Hendricks, R., Zhong, S., Liu, L., Adedeji, A. O., Chan, P., Schutten, M. M., Kamath, A. V., & Ovacik, M. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00744-8 · Cited by 11
Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans
Haraya, K., & Tachibana, T. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00917-8 · Cited by 11
A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey
Mahmood, I. (2021) · Antibodies · doi:10.3390/antib10030035 · Cited by 11
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Martinelli, I., Modica, C., Chiriaco, C., Basilico, C., Hughes, J. M., Corso, S., Giordano, S., Comoglio, P. M., & Vigna, E. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02320-6 · Cited by 11
PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species
Grimm, H. P., Schick, E., Hainzl, D., Justies, N., Yu, L., Klein, C., Husar, E., & Richter, W. F. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.07.013 · Cited by 10
Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
Ogasawara, A. K., Kiefer, J. R., Gill, H. S., Chiang, E., Sriraman, S. K., Ferl, G. Z., Ziai, J. M., Bohorquez, S. M. S., Guelman, S. A., Wang, X., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05968-6 · Cited by 10
Characterization and Interspecies Scaling of rhTNF-α Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models
Chen, X., DuBois, D. C., Almon, R. R., & Jusko, W. J. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074799 · Cited by 10
Predicting Method for the Human Plasma Concentration–Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates
Nakamura, G., Ozeki, K., Nagayasu, M., Nambu, T., Nemoto, T., & Hosoya, K. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-01042 · Cited by 10
Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach
Li, J., Nikanjam, M., Cunningham, C. K., McFarland, E. J., Coates, E. E., Houser, K. V., Lin, B. C., McDermott, A. B., Flach, B., Gama, L., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2026 · Cited by 10
Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model
Xin, Y., Xiang, H., Jin, D., Theil, F., Joshi, A., Damico‐Beyer, L. A., & Bai, S. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9244-6 · Cited by 10
Self-citation
Analytical Assay Platforms for Soluble Target Engagement Biomarkers: Old Favorites and Emerging Technologies
Goodman, J., & Agoram, B. M. (2013) · Bioanalysis · doi:10.4155/bio.13.262 · Cited by 10
Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys
Pai, R., Ma, N., Connor, A. V., Danilenko, D. M., Tarrant, J. M., Salvail, D., Wong, L., Hartley, D. P., Misner, D., Stefanich, E., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw037 · Cited by 9
An Evaluation of First-in-Human Studies for RNA Oligonucleotides
Stern, S., Wange, R. L., & Rogers, H. L. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2024.0036 · Cited by 9
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody
Belli, S., Amann, M., Hutchinson, L. G., Pousse, L., Abdolzade‐Bavil, A., Justies, N., Jacobsen, B., Ploix, C. C., Tselempi, E., Toševski, V., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3303 · Cited by 9
Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies
Ramakrishnan, V., Bender, B. C., Langenhorst, J. B., Magnusson, M. O., Dolton, M. J., Shim, J., Fuji, R. N., Monteiro, C., Teng, E., Kassir, N., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.146 · Cited by 9
Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor Xa I16L
Parng, C., Markiewicz, V., Chen, J., Leary, B. A., Duriga, N., Dyleski, L. A., Caiazzo, T., Bolt, M. W., Joyce, A. P., Gorovits, B., et al. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.03.035 · Cited by 10
Interspecies Scaling of Antibody–Drug Conjugates (ADC) for the Prediction of Human Clearance
Mahmood, I. (2021) · Antibodies · doi:10.3390/antib10010001 · Cited by 9
Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions
Marcantonio, D. H., Matteson, A., Presler, M., Burke, J. M., Hagen, D., Hua, F., & Apgar, J. F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.864768 · Cited by 9
Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases
Gardell, J. L., Maurer, M. E., Childs, M. M., Pham, M. N., Meengs, B., Julien, S. H., Tan, C., Boster, D. R., Quach, P., Therriault, J. H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1452537 · Cited by 8
First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers
Zhang, H., Zheng, W., Peng, R., Wu, D., Hu, Y., Sun, T., Gao, L., Liu, Y., Guo, L., Ding, Y., et al. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2453162 · Cited by 8
Evolution of human pharmacokinetics prediction methods: from allometry to artificial intelligence
Choi, N., Shin, B. S., & Shin, S. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00805-6 · Cited by 9
Comparison of Various Approaches to Translate Non-Linear Pharmacokinetics of Monoclonal Antibodies from Cynomolgus Monkey to Human
Singh, R., Moreno, M., & Stanimirovic, D. B. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00691-3 · Cited by 8
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
Grant, J., Hua, F., Apgar, J. F., Burke, J. M., & Marcantonio, D. H. (2023) · mAbs · doi:10.1080/19420862.2023.2192251 · Cited by 8
Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins
Kosloski, M. P., Pisal, D. S., Mager, D. E., & Balu‐Iyer, S. V. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23566 · Cited by 8
Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice
Piccand, M., Bessa, J., Schick, E., Senn, C., Bourquin, C., & Richter, W. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9850-5 · Cited by 8
Allometric Scaling of Therapeutic Monoclonal Antibodies Using Antigen Concentration as a Correction Factor: Application to the Human Clearance Prediction
Wang, L., Qiang, W., & Cheng, Z. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.12.021 · Cited by 8
Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5)
Ahlberg, J., Giragossian, C., Li, H., Myzithras, M., Raymond, E., Caviness, G. O., Grimaldi, C. M., Brown, S.-E., Perez, R., Yang, D., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1615345 · Cited by 8
A Cell-Based FcRn-dependent Recycling assay for Predictive Pharmacokinetic assessment of Therapeutic Antibodies
Liu, C., Kim, Y. S., Lowe, J. H.-N., & Chung, S. (2021) · Bioanalysis · doi:10.4155/bio-2021-0099 · Cited by 8
TNF ‐α level affects etanercept clearance: TNF ‐α concentration as a new correction factor of allometric scaling to predict individual etanercept clearances in patients with ankylosing spondylitis
Deng, Y., Hu, L., Qiang, W., Cheng, Z., Wang, L., & Wang, X. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12924 · Cited by 8
A Single-Species Approach Considering Additional Physiological Information for Prediction of Hepatic Clearance of Glycoprotein Derivate Therapeutics
Poulin, P. (2011) · Clinical Pharmacokinetics · doi:10.2165/11592610-000000000-00000 · Cited by 8
Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy
Chen, P., Bordeau, B. M., Zhang, W., & Balthasar, J. P. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01076-z · Cited by 7
Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC
Figueroa, I., Leipold, D., Leong, S. R., Zheng, B., Carrasco‐Triguero, M., Fourie-O’Donohue, A., Kozak, K. R., Xu, K., Schutten, M. M., Wang, H., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1465160 · Cited by 7
Translation of the efficacy of antibody–drug conjugates from preclinical to clinical using a semimechanistic PK / PD model: A case study with RC88
Li, Q., Wang, L., Zhang, J., Zhao, G., Liu, Z., Ma, X., & Jiang, J. (2023) · Clinical and Translational Science · doi:10.1111/cts.13526 · Cited by 7
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy
Yadav, R., Schubbert, S., Holder, P. G., Chiang, E. Y., Hassanzadeh‐Kiabi, N., Bogaert, L., Leung, I., Rashid, R., Avery, K. N., Bonzon, C., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1380000 · Cited by 7
The Effects of Interleukin‐6 Signal Blockade on Immune System, Reproductive and Skeletal Development in Juvenile Mice
Sakurai, T., Takai, R., Bürgin, H., Shioda, A., Sakamoto, Y., Amano, J., Grimm, H. P., Richter, W., Higuchi, Y., Chiba, S., et al. (2013) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.21053 · Cited by 7
Prediction of Human Pharmacokinetics Profile of Monoclonal Antibody Using hFcRn Transgenic Mouse Model
Nakamura, G., Ozeki, K., Takesue, H., Tabo, M., & Hosoya, K. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00775 · Cited by 7
PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer
Lee, E., Szvetecz, S., Polli, R., Grauel, A. L., Chen, J., Judge, J., Jaiswal, S., Maeda, R., Schwartz, S., Voedisch, B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93992-1 · Cited by 7
Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years
Oosterholt, S. P., & Pasqua, O. E. D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14893 · Cited by 7
Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey
Hardiansyah, D., & Ng, C. M. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.09.015 · Cited by 7

Authors: Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S.
Affiliations: Genentech (US)
Corresponding author: Deng, Rong
ORCID: Deng, Rong
Iyer, Suhasini
Theil, Frank-Peter
Prabhu, Saileta
Venue: mAbs
Publisher: Informa UK Limited
Published: 2011-01
Volume: 3
Issue: 1
Pages: 61-66
ISSN: 1942-0862 (ISSN-L)
1942-0870
DOI: 10.4161/mabs.3.1.13799
PMC: PMC3038012
OpenAlex: W1555185942
Cited by: 285
References: 24
Citations by year: 2026: 16 · 2025: 13 · 2024: 25 · 2023: 10 · 2022: 17 · 2021: 27 · 2020: 15 · 2019: 19 · 2018: 18 · 2017: 19 · 2016: 23 · 2015: 24 · 2014: 14 · 2013: 21 · 2012: 14
FWCI: 14.18
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc
Locations: mAbs (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Genentech
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords: therapeutic monoclonal antibodies, human pharmacokinetics, allometric scaling, clearance prediction, Macaca fascicularis, volume of distribution
MeSH terms: Algorithms, Animals, Antibodies, Monoclonal, Drug Evaluation, Preclinical, Humans, Macaca fascicularis, Metabolic Clearance Rate, Models, Biological, Species Specificity, Mice, Rats, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks